O. S. Usmani (London, United Kingdom), F. De Jongh (Enschede, Netherlands), T. Alnour (Khartoum North, Sudan)
Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol in vitro study validation
A.L. Fernandes, M.A. Lima, L.F.F. Pereira (Sao Paulo, Rio de Janeiro, Belo Horizonte, Brazil)
|  |
Consider the turbulent energy not inhalation flow when patients use dry powder inhalers (DPIs)
W. Azouz, P. Chetcuti, H. Hosker, D. Saralaya, H. Chrystyn (Leeds, Bradford, Steeton, United Kingdom)
|  |
The effect of airway alkalization by nebulized sodium bicarbonate on airway blood flow
A. Kis, L.A. Toth, L. Kunos, S. Vasas, G. Losonczy, E. Mendes, A. Wanner, G. Horvath (Budapest, Hungary; Miami, United States Of America)
| |
The investigation of inhalation continuous duration for dry powder inhalers in asthmatic patients
T. Niimi, Y. Shima, Y. Sakurai, T. Asano, A. Halata, Y. Tomita, Y. Takano, S. Sato, K. Akita, M. Banno, R. Matsushita, H. Ibata (Nagoya, Kanazawa, Tsu, Japan)
| |
Pharmacokinetics (PK) of single doses of mometasone furoate (MF) delivered via the Breezhaler® (BH) and Twisthaler® (TH) devices in healthy subjects
S. Vaidya, S. Khindri, J. Robinson, T. Smith, B. Magnusson, G. Kaiser, U. Malmqvist, B. Patterson (Cambridge, East Hanover, United States Of America; Horsham, United Kingdom; Basel, Switzerland; Lund, Sweden)
| |
An open-label trial to investigate the dose delivery and tolerability of inhaled dry powder mannitol (IDPM) using low output and high output OrbitalÔ inhalers across defined flow rates in healthy volunteers
G. Phillips, A. Redfern, J. Crapper, G. Mirella, B. Charlton (Frenchs Forest, Nedlands, Australia)
| |
Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler®
D. Singh, G. Lucci, D. Acerbi, S. Francesco, I. Montagna, S. Vezzoli, S. Khurana, G. Poli (Manchester, United Kingdom; Parma, Verona, Italy)
| |
Comparative in vitro performance of a new re-usable breath-actuated nebulizer (BAN) with other high performance systems intended for domiciliary use – 2: Portable battery-compressor
J. Malpass, M. Nagel, V. Avvakoumova, R. Ali, H. Schneider, J. Mitchell (London, Canada)
| |
The absorption, distribution, metabolism and excretion (ADME) of single oral doses of AZD5069, a novel CXCR2 antagonist, in healthy male volunteers
T. Mant, H. Wray, M. Cullberg, B. Larsson (London, United Kingdom; Mölndal, Sweden)
| |
Breaking microgram barrier to conduct dose ranging studies with long acting bronchodilators from a novel cosuspension metered dose inhaler product platform
V. Joshi, B. Noga, D. Lechuga-Ballesteros, R. Schultz, H. Cummings, M. Golden, C. Orevillo, C. Reisner, S. Dwivedi (Redwood City, Raleigh, Morristown, United States Of America)
| |
The pharmacokinetics (PK) and pharmacodynamics (PD) of the fluticasone furoate (FF) and vilanterol (VI) combination in subjects with severe renal impairment
A. Allen, K. Hardes, R. Kempsford, L. Tombs (Stevenage, Uxbridge, United Kingdom)
| |
Highly efficient dual and triple combination therapies with no coformulation effect for treatment of COPD
D. Lechuga-Ballesteros, V. Joshi, M. Sommerville, M. Golden, R. Vehring, B. Noga, H. Cummings, R. Schultz, C. Orevillo, C. Reisner, S. Dwivedi (Redwood City, Raleigh, Morristown, United States Of America)
| |
Absorption, distribution, metabolism, and elimination (ADME) of umeclidinium (UMEC) in healthy adults
D. Kelleher, S. Hughes, R. Mehta, L. Tombs, K. Kelly, A. Church (Research Triangle Park, United States Of America; Ware, Slough, Uxbridge, United Kingdom)
| |
Not all antistatic valved holding chambers have equivalent performance: An example why each valved holding chamber (VHC)-inhaler combination should be considered unique
J. Malpass, M. Nagel, V. Avvakoumova, R. Ali, H. Schneider, J. Mitchell (London, Canada)
| |
Design and implementation of a multi-part, flexible protocol to assess the tolerability and pharmacodynamic effects of PUR118 in healthy subjects and COPD patients
L. Patrick, A. Connor, S. Mair, J. Collier, M. Rosano, J. Hanrahan (Lexington, United States Of America; Nottingham, United Kingdom)
| |
Drug product stability of aclidinium bromide in Genuair®
S. Kurtz, K. Block, S. Folger, T. Pieper, B. Fyrnys (Bad Homburg, Germany)
| |
The pharmacokinetics (PK) and pharmacodynamics (PD) of the fluticasone furoate (FF) and vilanterol (VI) combination in subjects with hepatic impairment
A. Allen, K. Hardes, R. Kempsford, L. Tombs (Stevenage, Uxbridge, United Kingdom)
| |
No relevant drug-drug interaction between inhaled NVA237 and oral cimetidine
R. Sechaud, S. Dumitras, A. Drollmann, H. Hara, R. Karan, P. Pal, S. Vaidyanathan, G. Kaiser (Basel, Switzerland; Hyderabad, India)
| |
Drug-drug interactions in hospitalized patients with chronic obstructive pulmonary disease
T. Roblek, K. Trobec, A. Mrhar, M. Lainšc (Ljubljana, Golnik, Slovenia)
| |
Aerosol deposition in asthmatic subjects breathing helium-oxygen vs. air
C. Majoral, I. Katz, J. Fleming, J. Conway, L. Collier, M. Pichelin, L. Tossici-Bolt, G. Caillibotte (Jouy-en-Josas, France; Easton, United States Of America; Southampton, United Kingdom)
| |